NCT04662918 Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding
| NCT ID | NCT04662918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xingshun Qi |
| Condition | GastroIntestinal Bleeding |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-01-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.
Eligibility Criteria
Inclusion Criteria: 1. Patients with liver cirrhosis; 2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia; 3. Adults (age≥18 years old). Exclusion Criteria: 1. Components of Child-Pugh, MELD, and CAGIB scores are not available; 2. In-hospital outcomes are not evaluable.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04662918 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying GastroIntestinal Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04662918 currently recruiting?
Yes, NCT04662918 is actively recruiting participants. Contact the research team at xingshunqi@126.com for enrollment information.
Where is the NCT04662918 trial being conducted?
This trial is being conducted at Scranton, United States, São Paulo, Brazil, Beijing, China, Beijing, China and 11 additional locations.
Who is sponsoring the NCT04662918 clinical trial?
NCT04662918 is sponsored by Xingshun Qi. The trial plans to enroll 3,000 participants.